AU2013201809B2 - Tetrahydrocannabivarin (THCV) for use in the protection of pancreatic islet cells - Google Patents

Tetrahydrocannabivarin (THCV) for use in the protection of pancreatic islet cells Download PDF

Info

Publication number
AU2013201809B2
AU2013201809B2 AU2013201809A AU2013201809A AU2013201809B2 AU 2013201809 B2 AU2013201809 B2 AU 2013201809B2 AU 2013201809 A AU2013201809 A AU 2013201809A AU 2013201809 A AU2013201809 A AU 2013201809A AU 2013201809 B2 AU2013201809 B2 AU 2013201809B2
Authority
AU
Australia
Prior art keywords
thcv
use according
phytocannabinoid
diabetes
diabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013201809A
Other languages
English (en)
Other versions
AU2013201809A1 (en
Inventor
Michael Cawthorne
Colin Stott
Stephen Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Original Assignee
GW Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Pharma Ltd filed Critical GW Pharma Ltd
Publication of AU2013201809A1 publication Critical patent/AU2013201809A1/en
Application granted granted Critical
Publication of AU2013201809B2 publication Critical patent/AU2013201809B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2013201809A 2011-11-21 2012-11-20 Tetrahydrocannabivarin (THCV) for use in the protection of pancreatic islet cells Ceased AU2013201809B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1120066.4 2011-11-21
GB1120066.4A GB2496687A (en) 2011-11-21 2011-11-21 Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
PCT/GB2012/052869 WO2013076471A1 (en) 2011-11-21 2012-11-20 Tetrahydrocannabivarin (thcv) for use in the protection of pancreatic islet cells

Publications (2)

Publication Number Publication Date
AU2013201809A1 AU2013201809A1 (en) 2013-06-06
AU2013201809B2 true AU2013201809B2 (en) 2015-04-23

Family

ID=45475480

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013201809A Ceased AU2013201809B2 (en) 2011-11-21 2012-11-20 Tetrahydrocannabivarin (THCV) for use in the protection of pancreatic islet cells

Country Status (14)

Country Link
US (1) US20160243075A2 (enExample)
EP (2) EP2782568B1 (enExample)
JP (1) JP6338531B2 (enExample)
CN (1) CN103945841A (enExample)
AU (1) AU2013201809B2 (enExample)
BR (1) BR112014012159A2 (enExample)
CA (1) CA2856102A1 (enExample)
DK (1) DK2782568T3 (enExample)
ES (2) ES2560835T3 (enExample)
GB (2) GB2496687A (enExample)
MX (1) MX348564B (enExample)
PL (1) PL2782568T3 (enExample)
PT (1) PT2782568E (enExample)
WO (1) WO2013076471A1 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US10774288B2 (en) 2013-09-18 2020-09-15 The Werc Shop, LLC Terpene-based compositions, processes, methodologies for creation and products thereby
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
CN109804066A (zh) 2016-08-09 2019-05-24 哈佛大学的校长及成员们 可编程cas9-重组酶融合蛋白及其用途
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
AU2017342543B2 (en) 2016-10-14 2024-06-27 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
CA3057192A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
CN110575447B (zh) * 2018-06-07 2022-11-29 汉义生物科技（北京）有限公司 一种用于防治糖尿病的药物组合物及其用途
EP3804705B1 (en) * 2018-06-07 2023-09-13 Hanyi Bio-Technology Company Ltd. Pharmaceutical composition for preventing diabetes and use thereof
JP2021534141A (ja) * 2018-08-10 2021-12-09 セルビシオ アンダルーサ デ サルー アルコール使用障害の治療剤
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
EP3876704A4 (en) * 2018-11-09 2022-10-26 Agriculture Victoria Services Pty Ltd CANNABIS PLANTS WITH A CANNABINOID PROFILE ENRICHED WITH D-9-TETRAHYDROCANNABINOL, CANNABIGEROL AND TETRAHYDROCANNABIVARIN
DE112020001306T5 (de) 2019-03-19 2022-01-27 Massachusetts Institute Of Technology Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
EP4188363A4 (en) 2020-07-28 2024-10-16 Wsmef, Llc FULL-SPECTRUM HEMP OIL MICELLE PREPARATIONS FOR THE TREATMENT OF TYPE II DIABETES, REDUCING INFLAMMATION DURING COVID-19 AND IMPROVING SLEEP QUALITY
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
CN113135885A (zh) * 2021-04-07 2021-07-20 上海同田生物技术有限公司 一种高速逆流色谱分离纯化四氢次大麻酚的方法
US12011470B2 (en) 2021-07-28 2024-06-18 Clint Sorensen Micelle preparations of full-spectrum hemp oil
WO2024006896A1 (en) * 2022-06-29 2024-01-04 The Regents Of The University Of California Uses of hydrogenated cannabidiol (h4cbd) and advanced metabolic syndrome

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006054057A2 (en) * 2004-11-16 2006-05-26 Gw Pharma Limited New use for cannabinoid
WO2009093018A1 (en) * 2008-01-21 2009-07-30 Gw Pharma Limited New use for cannabinoids

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160420A0 (en) 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
GB0425248D0 (en) * 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
US20070060639A1 (en) * 2005-09-09 2007-03-15 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
KR101368525B1 (ko) * 2005-09-20 2014-03-06 노파르티스 아게 저혈당 증상을 저하시키기 위한 ｄｐｐ-ⅳ 억제제의 용도
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006054057A2 (en) * 2004-11-16 2006-05-26 Gw Pharma Limited New use for cannabinoid
WO2009093018A1 (en) * 2008-01-21 2009-07-30 Gw Pharma Limited New use for cannabinoids

Also Published As

Publication number Publication date
GB201120066D0 (en) 2012-01-04
BR112014012159A2 (pt) 2017-05-30
US20160243075A2 (en) 2016-08-25
DK2782568T3 (en) 2016-02-08
GB201220874D0 (en) 2013-01-02
EP3028697B1 (en) 2018-12-26
PT2782568E (pt) 2016-02-01
EP3028697A1 (en) 2016-06-08
WO2013076471A1 (en) 2013-05-30
PL2782568T3 (pl) 2016-05-31
EP2782568A1 (en) 2014-10-01
ES2714350T3 (es) 2019-05-28
CA2856102A1 (en) 2013-05-30
GB2496687A (en) 2013-05-22
AU2013201809A1 (en) 2013-06-06
US20160015682A2 (en) 2016-01-21
JP2014533680A (ja) 2014-12-15
ES2560835T3 (es) 2016-02-23
CN103945841A (zh) 2014-07-23
MX2014006057A (es) 2014-08-21
GB2496761A (en) 2013-05-22
JP6338531B2 (ja) 2018-06-06
US20140335208A1 (en) 2014-11-13
EP2782568B1 (en) 2015-10-28
MX348564B (es) 2017-06-20

Similar Documents

Publication Publication Date Title
AU2013201809B2 (en) Tetrahydrocannabivarin (THCV) for use in the protection of pancreatic islet cells
A Adeshara et al. Diabetes and complications: cellular signaling pathways, current understanding and targeted therapies
US20230285328A1 (en) Methods and Compositions for the Treatment of Steatosis-Associated Disorders
Brun et al. Postprandial reactive hypoglycemia
Zunino Type 2 diabetes and glycemic response to grapes or grape products
Nolan et al. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus
Kashani et al. Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression
Gibson et al. Randomized pilot study of cabergoline, a dopamine receptor agonist: effects on body weight and glucose tolerance in obese adults
Thulé Mechanisms of current therapies for diabetes mellitus type 2
Kane et al. Protection of neurons and microglia against ethanol in a mouse model of fetal alcohol spectrum disorders by peroxisome proliferator-activated receptor-γ agonists
Gupta et al. Obesity and diabetes: pathophysiology of obesity-induced hyperglycemia and insulin resistance
Li et al. Butyrate alleviates metabolic impairments and protects pancreatic β cell function in pregnant mice with obesity
Rameshrad et al. An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning
Vinik et al. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents
Campbell et al. β-cell preservation with thiazolidinediones
Old et al. The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review
Patel et al. Type-2 diabetes mellitus: A review of current trends
Mathur et al. A review on current type-2 diabetes mellitus treatment by selected phytoconstituents
Madoń et al. Classification, Symptoms, Treatment and Preventive Strategies of Diabetes. A guide to the basic
Sharifinejad et al. An Update on the Anti-diabetic Functions of Genistein: A Soybean (Glycine max (L.) Merr.) Isoflavone
US20150037361A1 (en) Compositions and methods to treat the bihormonal disorder in diabetes
De Fano et al. A new role for glucagon: from secondary hormone to key player
Padhye et al. Effect of turmeric on alloxan induced diabetes mellitus in albino rats
Boscarino et al. Chronic oral administration of clomipramine decreases sexual behavior in the male Syrian hamster (Mesocricetus auratus)
Reasner The Metabolic Syndrome: Identification and Management of the Patient at High Risk for Cardiovascular Disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired